Condom Maker Sold for a Boatload
August 27th, 2010 | No Comments | Source: Wall Street JournalUK-based consumer-products giant Reckitt Benckiser Group has entered the bedroom by acquiring SSL International, the maker of Durex, for $3.9 billion. Durex is the world’s best-selling condom brand.
Before purchasing the condom-maker, Reckitt had accumulated a ménage of decidedly unsexy products including d-Con mousetraps, Clearasil acne cream, Veet hair remover, Mucinex decongestant, Lysol disinfectants and Harpic toilet-bowl cleaner.
In marketing Durex, SSL had recently moved from a “safe sex” message to “better sex.” It introduced a line of lubricants and began selling vibrators in supermarkets and pharmacies. It also entered emerging markets like India and China. Durex sales rose nearly 5% last year, to $410 million.
In addition to condoms, the SSL deal allows Reckitt to market Scholl bunion pads outside the US (Merck has rights in the US), where they can enhance Reckitt’s already profitable line of OTC health care products including Gaviscon heartburn elixir and Strepsils cough drops. Even before the deal, health and personal care had been Reckitt’s largest market, accounting for about 40% of its $9.3 billion in sales.
In this market, shoppers will pay a premium for trusted brands, according to Julian Hardwick, a Royal Bank of Scotland analyst. “If you’ve got a sore throat, runny nose or splitting headache,” she explained to the Wall Street Journal, “You want something to sort that out for you. You really don’t care how much you pay for it.”
Reckitt’s offer of £11.71 per share was 45% above SSL’s average share price over the last 6 months. SSL shares traded below £5.50 just 9 months ago, suggesting the acquisition might have come a bit late for Reckitt.
The deal was prompted by pressure from consumer-goods colossus Procter & Gamble, which had been gaining market share vs. Reckitt in several categories in Western Europe over the last year.







One woman featured in a
In response, the ACGME recently proposed strict new guidelines which would, if adopted, curtail the duration of residents’ shifts and increase supervision requirements for those in charge of their care. The plan extends previous initiatives by the ACGME to limit the work hours of residents.
The FDA is not required to follow the recommendations of its panels, although it usually does.
The company is Emergent BioSolutions, and its BioThrax vaccine is its only product. Emergent has copped $1.4 billion in federal contracts for the vaccine in the last decade alone.
To reach these conclusions, the scientists performed a meta-analysis on 52 relevant articles on the subject, which were found during a systematic search of MEDLINE, PREMEDLINE and All EBM reviews. Together, the studies included a bit more than 3 million individuals.
The incentives are quite diverse. Some companies simply reward employees for getting a check-up evaluation or pay the costs of diet classes. Others pay employees that achieve certain exercise targets. Still others cut health-insurance premiums.
The companies, which include Hershey, Kraft Foods, Coca-Cola and Pepsico, announced plans to reach the goal by reducing portion sizes, changing recipes for certain products, and offering more low-cal alternatives to their offerings.
“We call it the first synthetic cell,” Craig Venter, the company founder who oversaw the project told the
Mildly overweight people do not have an increased risk of death from cancer or cardiovascular disease-In a study published in JAMA, Katherine Flegal and colleagues from the CDC looked at mortality rates reported in NHANES, an annual health survey. They found that mortality among those classified as overweight was lower than they had estimated. By contrast, those classified as underweight and obese had higher mortality rates than had been predicted.
The biopsy is expensive and not without risk however, so scientists have long searched for a non-invasive alternative to diagnose rejection.
In the 6-week study, Jessica Grahn and colleagues at the Medical and Research Council’s Cognition and Brain Sciences Unit in Cambridge, England randomized 11,430 healthy participants to one of 3 groups. The first engaged in online games designed to improve general intelligence skills like problem-solving and reasoning. The second group performed exercises aimed at increasing attention, short-term memory and mathematical skills—the focus of commercial brain-training programs. The control group browsed the Internet in search of answers to general knowledge questions.
The FDA never did say who was responsible for the outbreak, which caused 




